RU2021101009A - Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство - Google Patents

Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство Download PDF

Info

Publication number
RU2021101009A
RU2021101009A RU2021101009A RU2021101009A RU2021101009A RU 2021101009 A RU2021101009 A RU 2021101009A RU 2021101009 A RU2021101009 A RU 2021101009A RU 2021101009 A RU2021101009 A RU 2021101009A RU 2021101009 A RU2021101009 A RU 2021101009A
Authority
RU
Russia
Prior art keywords
antibody
fragments
predetermined capping
capped
group
Prior art date
Application number
RU2021101009A
Other languages
English (en)
Inventor
Сяотянь ЧЖУН
Амарнаут Шастри ПРАШАД
Рональд Уильям КРИЗ
Тао ХИ
Уилл СОМЕРС
Венге ВАН
Лео Джозеф ЛЕТЕНДРЕ
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2021101009A publication Critical patent/RU2021101009A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (9)

1. Способ получения конъюгата лекарственного средства с антителом (ADC), включающий стадии:
(a) получения кэпированного антитела в клеточной культуре, причем один или несколько непарных остатков цистеина на указанном антителе являются ковалентно связанными посредством связей серы с одним или несколькими предварительно определенными фрагментами кэпирования, где указанные предварительно определенные фрагменты кэпирования выбирают из группы, состоящей из:

и
Figure 00000001
где R представляет собой алкил, алкенил, алкинил, арил, гетероарил, альдегид, кетон или цитотоксическую нагрузку; и
(b) необязательно дополнительно взаимодействие указанного предварительно определенного фрагмента кэпирования на указанном кэпированном антителе.
2. Способ по п. 2, где указанную цитотоксическую нагрузку выбирают из группы, состоящей из ауристатинов, калихеамицинов, майтанзиноидов, сплайсостатинов, димеров CBI, димеров CPI и димеров CTI.
3. Способ получения конъюгата лекарственного средства с антителом (ADC), включающий стадии:
(a) получения кэпированного антитела в клеточной культуре, причем один или несколько непарных остатков цистеина на указанном антителе являются ковалентно связанными посредством связей серы с одним или несколькими предварительно определенными фрагментами кэпирования, где указанные предварительно определенные фрагменты кэпирования выбирают из группы, состоящей из: малеимидотриокса-4-формилбензамида (MTFB), дибензоциклооктил-полиэтиленмалеимада (DBCO-PEG4-малеимида) и азидо-ПЭГ3-малеимида; и
(b) необязательно дополнительно взаимодействие указанного предварительно определенного фрагмента кэпирования на указанном кэпированном антителе.
RU2021101009A 2015-08-12 2016-08-09 Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство RU2021101009A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562204005P 2015-08-12 2015-08-12
US62/204,005 2015-08-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018105128A Division RU2742260C2 (ru) 2015-08-12 2016-08-09 Кэпированные и некэпированные цистеины антитела и их применение в конъюгации антитело-лекарственное средство

Publications (1)

Publication Number Publication Date
RU2021101009A true RU2021101009A (ru) 2021-02-20

Family

ID=56855760

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018105128A RU2742260C2 (ru) 2015-08-12 2016-08-09 Кэпированные и некэпированные цистеины антитела и их применение в конъюгации антитело-лекарственное средство
RU2021101009A RU2021101009A (ru) 2015-08-12 2016-08-09 Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2018105128A RU2742260C2 (ru) 2015-08-12 2016-08-09 Кэпированные и некэпированные цистеины антитела и их применение в конъюгации антитело-лекарственное средство

Country Status (20)

Country Link
US (2) US10653794B2 (ru)
EP (2) EP3334760B1 (ru)
JP (2) JP6865209B2 (ru)
KR (2) KR102319622B1 (ru)
CN (1) CN107849121B (ru)
AU (1) AU2016305331B2 (ru)
BR (1) BR112018001904A2 (ru)
CA (1) CA2938333A1 (ru)
DK (1) DK3334760T3 (ru)
ES (1) ES2864842T3 (ru)
HK (1) HK1252799A1 (ru)
HR (1) HRP20210579T1 (ru)
HU (1) HUE053956T2 (ru)
IL (1) IL257420B (ru)
MX (1) MX2018001686A (ru)
PL (1) PL3334760T3 (ru)
PT (1) PT3334760T (ru)
RU (2) RU2742260C2 (ru)
SI (1) SI3334760T1 (ru)
WO (1) WO2017025897A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018001904A2 (pt) * 2015-08-12 2018-09-18 Pfizer cisteínas de anticorpos rematados e não rematados, e seu uso na conjugação anticorpo-fármaco
US20190381182A1 (en) 2017-02-08 2019-12-19 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation
WO2020164561A1 (en) 2019-02-15 2020-08-20 Wuxi Biologics (Shanghai) Co. Ltd. Process for preparing antibody-drug conjugates with improved homogeneity
IL303951A (en) * 2020-12-22 2023-08-01 Novartis Ag Methods for reducing the oxidation level of cysteine residues in recombinantly secreted protein during cell culture
WO2023067626A1 (en) * 2021-10-20 2023-04-27 Dr. Reddy's Laboratories Limited A cell culture process to produce an antibody composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ATE526401T1 (de) * 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
JP4249028B2 (ja) * 2001-12-04 2009-04-02 田辺三菱製薬株式会社 蛋白質の活性化方法
JP5335422B2 (ja) * 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
RU2424246C2 (ru) * 2006-05-26 2011-07-20 Ипсен Фарма С.А.С. Способы сайт-специфического пегилирования
US8612161B2 (en) * 2008-03-19 2013-12-17 Intelligent Biosystems Inc. Methods and compositions for base calling nucleic acids
PL2586788T3 (pl) * 2007-07-09 2018-05-30 Genentech, Inc. Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
WO2009092011A1 (en) * 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
WO2011041721A1 (en) * 2009-10-02 2011-04-07 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
EP3778917A3 (en) * 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
MX336540B (es) * 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
MX339533B (es) * 2011-05-27 2016-05-30 Abbvie Biotechnology Ltd Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
EP2818480B1 (en) * 2012-02-24 2020-08-26 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
US9018172B2 (en) 2012-09-26 2015-04-28 Massachusetts Institute Of Technology Modification of peptides via SNAr reactions of thiols with fluorinated aromatics
AR098221A1 (es) * 2013-11-04 2016-05-18 Pfizer Conjugados de anticuerpo anti-efna4-fármaco
EP3077522A1 (en) * 2013-12-04 2016-10-12 Immunogen, Inc. Compositions and methods for antibody production
AU2015208814B2 (en) 2014-01-27 2018-11-01 Pfizer Inc. Bifunctional cytotoxic agents
SG11201706991YA (en) 2015-03-20 2017-10-30 Pfizer Bifunctional cytotoxic agents containing the cti pharmacophore
BR112018001904A2 (pt) * 2015-08-12 2018-09-18 Pfizer cisteínas de anticorpos rematados e não rematados, e seu uso na conjugação anticorpo-fármaco

Also Published As

Publication number Publication date
AU2016305331A1 (en) 2018-02-15
EP3334760A2 (en) 2018-06-20
KR20200100850A (ko) 2020-08-26
US20190030183A1 (en) 2019-01-31
RU2742260C2 (ru) 2021-02-04
IL257420A (en) 2018-06-28
CN107849121A (zh) 2018-03-27
HUE053956T2 (hu) 2021-08-30
SI3334760T1 (sl) 2021-07-30
WO2017025897A3 (en) 2017-04-06
JP6865209B2 (ja) 2021-04-28
WO2017025897A2 (en) 2017-02-16
PT3334760T (pt) 2021-04-23
ES2864842T3 (es) 2021-10-14
US10653794B2 (en) 2020-05-19
DK3334760T3 (da) 2021-04-19
KR102319622B1 (ko) 2021-11-02
US11980669B2 (en) 2024-05-14
AU2016305331B2 (en) 2019-05-16
PL3334760T3 (pl) 2021-10-11
EP3808768A1 (en) 2021-04-21
IL257420B (en) 2022-08-01
BR112018001904A2 (pt) 2018-09-18
KR102146617B1 (ko) 2020-08-20
HRP20210579T1 (hr) 2021-05-28
MX2018001686A (es) 2019-01-31
EP3334760B1 (en) 2021-03-10
CN107849121B (zh) 2021-11-09
KR20180038041A (ko) 2018-04-13
RU2018105128A (ru) 2019-09-12
US20200230256A1 (en) 2020-07-23
HK1252799A1 (zh) 2019-06-06
RU2018105128A3 (ru) 2020-07-27
JP2021118694A (ja) 2021-08-12
JP2018525990A (ja) 2018-09-13
CA2938333A1 (en) 2017-02-12

Similar Documents

Publication Publication Date Title
RU2021101009A (ru) Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство
WO2018098269A3 (en) Peptide-containing linkers for antibody-drug conjugates
RU2019109456A (ru) Новые конъюгаты антител и их применения
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
BR112016002829A2 (pt) Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
EP3792278A3 (en) Human anti-tau antibodies
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
DK3276349T3 (da) Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåder til fremstilling og anvendelse deraf
EA201690744A1 (ru) Конъюгаты белок-полимер-лекарственное средство
WO2017004026A8 (en) Anti-cd123 antibodies and conjugates and derivatives thereof
DK1594542T3 (da) Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
WO2015151081A3 (en) Bridge linkers for conjugation of cell-binding molecules
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2019215510A8 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
NL1033650A1 (nl) Antilichamen tegen myostatine.
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
DE602005025531D1 (de) Saccharid-konjugatvakzine
AR102649A1 (es) Anticuerpos anti-cadherina-p y conjugados anticuerpos-fármacos
EP3695852A4 (en) ANTI-MESOTHELIN ANTIBODY AND ANTIBODY-ASSOCIATED DRUG CONJUGATE